


EXCLUSIVE LICENSE PRECLINICAL COLLABORATION

to Develop Kainos' Patented IRAK4 Inhibitor (KM10544) as Anti-Cancer Drug in NAFTA/Europe





This is a selection of the tags about this deal. For all tags related to this deal, log into BioSciDB

Research & Development (8)

— Scope of Agreement (3)

Modifier: Disease Indications

"Field of Use" means treatment of cancers, including but not limited to leukemia, lymphoma, and solid tumor cancers.

Page: 2

Modifier: Technology

WHEREAS, KM10544 is one of the N-(1H-Imidazol-2-yl) benzamide compounds (the **"Claimed Compounds"**) claimed in patent application number PCT/KR2020/013397, titled N (1H-IMIDAZOL-2-YL) BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT (the **"Patent Application"**); and

Page: 1

Modifier: Technology

"Licensed Product" and **"Licensed Products"** mean (a) any and all products that include KM10544, (i) the manufacture, use, offer for sale, sale, or importation of which by Licensee would, in the absence of a license granted under, or ownership of, the Licensed Patents, infringe a Valid Claim or (ii) that incorporates or embodies any Know-How, and (b) any other products the Parties may agree upon in writing from time to time.